金宇生物技术股份有限公司回购注销部分股票及注册资本减少，发布债权人通知公告
要点摘要
- 公司名称：金宇生物技术股份有限公司（证券代码：600201）
- 公告日期：2026年5月19日
- 回购注销股份数量：共计1,182万股，包括2023年员工持股计划中未解锁权益份额的851.84万股，以及公司回购专用证券账户中使用期限满三年的回购股份330.16万股
- 股份总数及注册资本变化：股份总数由1,111,747,826股减少至1,099,927,826股，注册资本由人民币1,111,747,826元减少至1,099,927,826元
- 债权人通知期：自公告发布之日起45日内，可向公司申报债权，要求清偿债务或要求公司提供担保
- 本次股份注销事项已于2026年4月22日通过公司董事会审议，相关内容已披露于2026年5月14日上海证券交易所网站
- 申报材料及联系方式：详见下文“债权申报说明”
对股东和投资者的重要影响与潜在股价影响
- 注册资本减少：本次回购注销股份将导致公司注册资本减少，减少的股份主要为员工持股计划未解锁部分以及回购满三年股份。这将直接影响公司每股收益（EPS）等指标，理论上对每股收益具有提升作用，或对股东价值形成一定正面影响。
- 员工持股计划调整：回购注销未解锁员工持股计划股份，可能意味着部分激励计划未达成或调整，对公司未来激励机制和员工信心有一定影响。
- 债权人权利保障：根据《公司法》规定，债权人可在45日内主张权利，公司需继续履行原债务安排。此举显示公司合规操作，降低法律风险。
- 股份流通与市场供需：注销股份将减少市场流通总量，从理论上看有助于支撑股价，投资者需关注市场对此消息的反应。
- 公告透明度：本次事项经董事会审议通过并依法公告，信息披露较为及时与充分，有助于维护投资者信心。
详细内容与操作指引
金宇生物技术股份有限公司于2026年4月22日召开第十二届董事会第五次会议，通过了《关于拟回购注销2023年员工持股计划部分股票及注销回购专用证券账户中部分股票的议案》。公司将对2023年员工持股计划已授予但尚未解锁的权益份额，对应的851.84万股，以及回购专用证券账户中使用期限满三年的回购股份330.16万股进行回购注销。注销完成后，公司股份总数从11.12亿股减少至10.99亿股，注册资本相应减少。
公司依据《中华人民共和国公司法》等规定，主动通知所有债权人，在公告披露之日起45日内，持有效债权证明材料可向公司申报债权，要求清偿或提供担保。若债权人在期限内未申报，不影响其债权有效性，公司仍将根据原约定履行债务。
债权申报说明
- 申报时间：2026年5月19日至2026年7月2日（工作日9:00-11:30，14:00-17:00）
- 申报地址：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大街1号金宇生物技术股份有限公司董事会办公室
- 联系人：刘艺坤、郝剑飞
- 联系电话：0471-6539434
- 传真：0471-6539434
- 邮政编码：010111
- 申报方式：现场、邮寄、传真均可。邮寄以邮戳日为准，传真以公司收到文件日为准，须注明“申报债权”字样。
- 需提交材料：
- 证明债权债务关系的合同、协议及凭证原件及复印件
- 法人：营业执照副本原件及复印件、法定代表人身份证明文件，委托他人办理的还需授权委托书及代理人身份证明
- 自然人：身份证原件及复印件，委托他人办理的需授权委托书及代理人身份证明
结论
本次回购注销股份以及注册资本减少，属于公司资本结构优化、激励计划调整的重要举措，预计将对每股收益等财务指标产生一定正面影响。短期内可能成为推动公司股价波动的敏感信息，建议投资者密切关注公司动态与后续公告。
免责声明：本资讯仅供投资者参考，不构成投资建议。投资有风险，入市需谨慎。信息基于公司公告内容整理，若有疑问请以公司官方公告及法律文件为准。
English Version
Jinyu Bio-Technology Co., Ltd. Announces Share Buyback and Capital Reduction, Notifies Creditors
Key Highlights
- Company Name: Jinyu Bio-Technology Co., Ltd. (Stock Code: 600201)
- Announcement Date: May 19, 2026
- Total Shares to be Cancelled: 11.82 million shares, including 8.5184 million shares from the 2023 Employee Share Ownership Plan (unlocked rights) and 3.3016 million shares from repurchase shares held for three years
- Share Capital Change: Total shares will decrease from 1,111,747,826 to 1,099,927,826; registered capital will decrease accordingly from RMB 1,111,747,826 to RMB 1,099,927,826
- Creditor Notification Period: Within 45 days from the announcement date, creditors can declare claims or request guarantees
- This share cancellation was approved at the board meeting on April 22, 2026, and details were disclosed on the SSE website on May 14, 2026
- Details on declaration materials and contacts: See below in “Claim Declaration Instructions”
Important Information and Potential Share Price Sensitivity
- Reduction in Registered Capital: The buyback and cancellation will reduce registered capital, mainly from unvested employee shares and repurchased shares held for three years. This could improve EPS and may positively impact shareholder value.
- Adjustment of Employee Incentive Plan: Cancelling unvested employee shares may indicate unmet targets or plan adjustments, potentially impacting future incentive schemes and staff morale.
- Creditor Rights: As per PRC Company Law, creditors can declare claims within 45 days. The company continues to fulfill all original debt obligations, indicating compliance and reduced legal risk.
- Share Supply Impact: The reduction in shares outstanding could support the share price, depending on market perception.
- Transparency: The matter was approved and disclosed in accordance with regulations, which helps maintain investor confidence.
Detailed Content and Operational Guidance
Jinyu Bio-Technology Co., Ltd. held its 12th board’s 5th meeting on April 22, 2026, approving the buyback and cancellation of 8.5184 million shares from unvested rights in the 2023 Employee Share Ownership Plan and 3.3016 million shares held for three years. After cancellation, total shares will decrease from 1.111 billion to 1.099 billion, with a corresponding decrease in registered capital.
According to the Company Law, creditors are notified and may submit claims within 45 days. If no claim is submitted within the period, the validity of the claim is not affected, and the company will fulfill obligations as per original agreements.
Claim Declaration Instructions
- Declaration Period: May 19, 2026 to July 2, 2026 (Weekdays 9:00–11:30, 14:00–17:00)
- Address: Board Office, Jinyu Bio-Technology Co., Ltd., No.1 Jinyu Avenue, Shaerqin Industrial Park, Economic and Technological Development Zone, Hohhot, Inner Mongolia
- Contacts: Liu Yikun, Hao Jianfei
- Tel: 0471-6539434
- Fax: 0471-6539434
- Postal Code: 010111
- Methods: Onsite, mail, or fax. For mail, the postmark date applies; for fax, the date received applies. Please indicate “Claim Declaration”.
- Required Materials:
- Original and copy of contracts or evidence of debt
- For entities: business license original/copy, legal representative’s ID; if by agent, also POA and agent’s ID
- For individuals: ID original/copy; if by agent, also POA and agent’s ID
Conclusion
The share buyback and capital reduction reflect ongoing capital structure optimization and incentive plan adjustment. These changes may positively impact per-share financial metrics and could be price-sensitive. Investors are advised to follow subsequent disclosures and developments closely.
Disclaimer: This information is for reference only and does not constitute investment advice. Please make decisions cautiously and refer to official company disclosures and legal documents in case of doubt.
